Breast cancer drug approved for NHS after maker agrees discount

Reversal of earlier rejection by Nice of abemaciclib - known as Verzenios - is welcomed by campaigners

A breast cancer drug that was rejected for routine NHS use in England earlier this year has now been recommended by health officials after a discount was agreed with the manufacturer.

The decision has been described as fantastic news for thousands of women" by a charity, which said the introduction of this drug would give precious extra months" for those who are very unwell.